Akebia Therapeutics (AKBA) Net Cash Flow Growth (5y) (2018 - 2026)
Akebia Therapeutics (AKBA) Net Cash Flow Growth (5y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.15 Bn | 87.28 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.85 Bn | 32.11 Bn | 1.97 Bn |
| 3 | Zoetis | 32.52 Bn | 30.58 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.53 Bn | 23.47 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.21 Bn | 21.06 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - |
| 7 | Viatris | 20.30 Bn | 18.50 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.42 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.59 Bn | 12.16 Bn | 785.00 Mn |
| 10 | Akebia Therapeutics | 340.48 Mn | 177.88 Mn | 41.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.05% |
| Dec 31, 2025 | -20.89% |
| Sep 30, 2025 | 18.96% |
| Jun 30, 2025 | -28.71% |
| Mar 31, 2025 | 31.43% |
| Dec 31, 2024 | -6.18% |
| Sep 30, 2024 | -16.59% |
| Jun 30, 2024 | -16.00% |
| Mar 31, 2024 | 53.04% |
| Dec 31, 2023 | 42.43% |
| Sep 30, 2023 | -45.38% |
| Jun 30, 2023 | -22.65% |
| Mar 31, 2023 | -18.94% |
| Dec 31, 2022 | -22.97% |
| Sep 30, 2022 | 15.15% |
| Jun 30, 2022 | -22.90% |
| Mar 31, 2022 | 17.69% |
| Dec 31, 2021 | -19.85% |
| Sep 30, 2021 | -32.11% |
| Jun 30, 2021 | -32.66% |